[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Fetsch
T
T
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D006801:Humans; D010919:Placebos; D011802:Quinidine / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013015:Sotalol / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D010919:Placebos; D013015:Sotalol; D014700:Verapamil; D011802:Quinidine